Investigation of the physico-chemical properties that enable co-formulation of basal insulin degludec with fast-acting insulin aspart

Pharmaceutical Research

Volumn 32, Issue 7, 2015, Pages 2250-2258

  Havelund, Svend ^a   Ribel, Ulla ^a   Hubálek, František ^a   Hoeg Jensen, Thomas ^a   Wahlund, Per Olof ^a   Jonassen, Ib ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

co formulation; insulin analog; insulin aspart; insulin degludec

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; META CRESOL; MONOMER; PHENOL; ZINC; ANTIDIABETIC AGENT; DRUG COMBINATION; INSULIN DEGLUDEC, INSULIN ASPART DRUG COMBINATION; LONG ACTING INSULIN; PRESERVATIVE;

ARTICLE; CONTROLLED STUDY; DISSOCIATION; DRUG FORMULATION; GEL PERMEATION CHROMATOGRAPHY; HUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; SIMULATION; BIOLOGICAL MODEL; CHEMISTRY; DRUG COMBINATION; MEDICINAL CHEMISTRY; METABOLISM; PHOTON CORRELATION SPECTROSCOPY; SIZE EXCLUSION CHROMATOGRAPHY; SUBCUTANEOUS DRUG ADMINISTRATION;

CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, REVERSE-PHASE; DRUG COMBINATIONS; DYNAMIC LIGHT SCATTERING; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN ASPART; INSULIN, LONG-ACTING; MODELS, BIOLOGICAL; PRESERVATIVES, PHARMACEUTICAL;

EID: 84930178610     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1614-x     Document Type: Article

References (23)

1. Emdin SO, Dodson GG, Cutfield JM, Cutfield SM. Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell. Diabetologia. 1980;19(3):174-82.
2. Polonsky KS, Sturis J, Bell GI. Seminars in medicine of the beth Israel hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996;334(12):777-83.
3. Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol. 2002;16(3):475-92.
4. Krayenbühl C, Rosenberg T. Crystalline protamine insulin. Rep Steno Mem Hosp Nord Insulin lab. 1946;1:60-73.
5. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142-8.
6. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23(5):644-9.
7. Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28(5):1107-12.
8. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614-20.
9. Vora J, Heise T. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Diabetes Obes Metab. 2013;15(8):701-12.
10. Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356(9228):443-5.
11. Havelund S, Plum A, Ribel U, Jonassen I, Vølund A, Markussen J, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21(8):1498-504.
12. Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care. 2010;33(5):1009-12.
13. Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA. The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin. Diabetes Care. 2012;35(4):690-2.
14. Heise T, Nosek L, Roepstorff C, Chenji S, Klein O, Haahr H. Distinct prandial and basal glucose-lowering effects of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus. Diabetes Ther. 2014;5(1):255-65.
15. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29(8):2104-14.
16. Steensgaard DB, Schluckebier G, Strauss HM, Norrman M, Thomsen JK, Friderichsen AV, et al. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry. 2013;52(2):295-309.
17. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859-64.
18. Jonassen I, Hoeg-Jensen T, Havelund S, Ribel-Madsen U, Tagmose TM, Madsen P. New insulin derivative comprising a naturally occurring insulin with a side chain attached to the alpha-amino or epsilon-amino in the B chain of the parent insulin, useful in composition for treating diabetes. Patent registered by Novo Nordisk A/S and published in the Derwent World Patents Index (DWPI). Patent no. WO2005012347-A2.
19. Jensen MH, Wahlund PO, Toft KN, Jacobsen JK, Steensgaard DB, van de Weert M, et al. Small angle X-ray scattering-based elucidation of the self-association mechanism of human insulin analogue lys(B29)(N(ε)ω-carboxyheptadecanoyl) des(B30). Biochemistry. 2013;52(2):282-94.
20. Xu Y, Yan Y, Seeman D, Sun L, Dubin PL. Multimerization and aggregation of native-state insulin: effect of zinc. Langmuir. 2012;28(1):579-86.
21. Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M, et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol. 2012;167(2):287-94.
22. Christiansen JS, Chow FCC, Choi DS, Taneda S, Hirao K. Superior FPG control and less nocturnal hypoglycaemia with IDegAsp vs BIAsp 30 in Asian subjects poorly controlled on basal or pre/self-mixed insulin: randomised phase 3 trial. Diabetologia. 2013;56(1):S420. abstract 1045.
23. Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH, et al. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014;37(8):2084-90.